Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2026 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Rhythm Pharmaceuticals First Quarter 2026 Earnings Conference Call.
Rhythm Pharmaceuticals Inc. (RYTM)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ZWEIG DIMENNA PARTNERS Joe Dimenna | 0 | $0 | 0% | |
| 2. | Bayforest Capital Theodoros Tsagaris | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.17 | 10,000 | $201,713.00 | 111,335 | 2021-03-30 | Filing | |
| $26.42 | 378,501 | $9,999,996.42 | 3,074,893 | 2018-06-25 | Filing | |
| $17.00 | 100,000 | $1,700,000.00 | 2,696,392 | 2017-10-10 | Filing | |
| $17.00 | 100,000 | $1,700,000.00 | 2,696,392 | 2017-10-10 | Filing | |
| $17.00 | 550,000 | $9,350,000.00 | 4,909,956 | 2017-10-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $89.56 | 5,614 | $502,789.84 | 160 | 2026-03-04 | Filing | |
| $103.28 | 585 | $60,420.44 | 110,512 | 2026-02-19 | Filing | |
| $102.10 | 800 | $81,676.08 | 111,097 | 2026-02-19 | Filing | |
| $100.92 | 1,692 | $170,754.78 | 111,897 | 2026-02-19 | Filing | |
| $100.27 | 1,308 | $131,152.90 | 113,589 | 2026-02-19 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,040,718 | $264,451,244 | 0.01% | |
| 2. | 2,967,825 | $258,111,740 | 0.01% | |
| 3. | 667,046 | $57,329,169 | 0.06% | |
| 4. | 464,340 | $40,383,650 | 0.21% | |
| 5. | 421,911 | $36,693,600 | 0.01% |
News See All
Billionaire Joe Edelman's 10 Stock Picks with Huge Upside Potential
Joseph Edelman, the billionaire chief of New York-based Perceptive Advisors, specializes in the biotechnology and life sciences sectors.
Is Rhythm Pharmaceuticals, Inc. (RYTM) A Good Stock To Buy Now?
Is RYTM a good stock to buy? We came across a bearish thesis on Rhythm Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bears’ thesis on RYTM.
15 Most Promising Stocks Under $100 to Buy
On March 12, Roger Ferguson, former Fed Vice Chair, joined 'Closing Bell' on CNBC to discuss what to expect from the Federal Reserve next week.
Top 10 Boring Stocks That Make Money
Investors have been concentrating on businesses with solid fundamentals, steady cash flows, and long-lasting competitive advantages that can produce steady profit growth in a market influenced by fluctuating...
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2025 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2025 Earnings Call Transcript February 26, 2026Rhythm Pharmaceuticals, Inc. beats earnings expectations.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2025 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2025 Earnings Call Transcript November 4, 2025Rhythm Pharmaceuticals, Inc. misses on earnings expectations.
Should You Expect Robust Growth Potential for Rhythm Pharmaceuticals (RYTM) Ahead?
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.
10 Hot Mid Cap Stocks to Buy Now
On Friday, August 29, stocks declined as investors decided to take some money out before a long weekend.
13 Best Mid Cap Growth Stocks to Buy According to Hedge Funds
On August 26, Courtney Garcia, Payne Capital Management senior wealth advisor, joined CNBC television for an interview to discuss whether investors should continue buying in the current market scenario...
Hedge Fund Resource Center